Skip to main content

Table 2 Subgroup analysis of the impact of anti-tumor therapy on death and severe disease of cancer patients with COVID-19

From: The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

Anti-tumor therapy

Solid tumour

Haematological malignancy

death

severe COVID-19

death

severe COVID-19

OR (95%CI)

P

OR (95%CI)

P

OR (95%CI)

P

OR (95%CI)

P

Chemotherapy

1.17 (1.03–1.34)

0.0158

1.16 (0.81–1.66)

0.4072

1.41 (0.74–2.68)

0.2964

NA

NA

Radiotherapy

NA

NA

NA

NA

NA

NA

NA

NA

Targeted therapy

NA

NA

NA

NA

NA

NA

NA

NA

Surgery

NA

NA

NA

NA

NA

NA

NA

NA

Endocrine therapy

NA

NA

NA

NA

NA

NA

NA

NA

Immunotherapy

0.91 (0.47–1.76)

0.7705

NA

NA

NA

NA

NA

NA

Antitumor therapy

1.15 (0.94–1.42)

0.1815

1.08 (0.88–1.32)

0.4643

1.26 (0.91–1.75)

0.1597

NA

NA

  1. Abbreviations NA Not available, OR Odds ratio, CI Confidence interval